{
    "Clinical Trial ID": "NCT00091442",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Docetaxel",
        "  Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.",
        "INTERVENTION 2: ",
        "  DOXIL+Docetaxel",
        "  DOXIL and docetaxel combination: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Females with locally advanced or metastatic breast cancer who received prior anthracycline therapy in the neoadjuvant or adjuvant setting, and had at least a 12-month disease-free interval since the end of their last cytotoxic therapy, were eligible for the study",
        "  Participants who received prior hormonal therapy, or no more than 1 cytotoxic chemotherapy regimen (anthracyclines, taxanes, or antitubulin agents were not permitted), or both for advanced disease",
        "  Participants with normal cardiac function, as evidenced by a normal left ventricular ejection fraction",
        "Exclusion Criteria:",
        "  More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer",
        "  Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel, vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen that included alkylating agents or antimetabolite agents was acceptable)",
        "  Less than 2 months since the last dose of trastuzumab",
        "  Less than 3 weeks since last dose of tamoxifen or fulvestrant, or less than 1 week since the last dose of other hormonal therapy",
        "  Radiation to areas of disease within 30 days before study enrollment",
        "  History of New York Heart Association Class II or greater cardiac disease or other clinical evidence of congestive heart failure"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Time to Progression",
        "  Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.",
        "  Time frame: From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled",
        "Results 1: ",
        "  Arm/Group Title: Docetaxel",
        "  Arm/Group Description: Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.",
        "  Overall Number of Participants Analyzed: 373",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  7.0        (5.9 to 7.7)",
        "Results 2: ",
        "  Arm/Group Title: DOXIL+Docetaxel",
        "  Arm/Group Description: DOXIL and docetaxel combination: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.",
        "  Overall Number of Participants Analyzed: 378",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  9.8        (8.1 to 10.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 59/373 (15.82%)",
        "  Neutropenia 14/373 (3.75%)",
        "  Febrile neutropenia 10/373 (2.68%)",
        "  Leukopenia 1/373 (0.27%)",
        "  Anaemia 2/373 (0.54%)",
        "  Lymphadenopathy 0/373 (0.00%)",
        "  cardiac failure 2/373 (0.54%)",
        "  Atrial fibrillation 1/373 (0.27%)",
        "  Pericardial effusion 2/373 (0.54%)",
        "  Cardiac failure congestive 1/373 (0.27%)",
        "  Cardiomyopathy 0/373 (0.00%)",
        "Adverse Events 2:",
        "  Total: 69/377 (18.30%)",
        "  Neutropenia 17/377 (4.51%)",
        "  Febrile neutropenia 10/377 (2.65%)",
        "  Leukopenia 4/377 (1.06%)",
        "  Anaemia 2/377 (0.53%)",
        "  Lymphadenopathy 1/377 (0.27%)",
        "  cardiac failure 1/377 (0.27%)",
        "  Atrial fibrillation 1/377 (0.27%)",
        "  Pericardial effusion 0/377 (0.00%)",
        "  Cardiac failure congestive 0/377 (0.00%)",
        "  Cardiomyopathy 1/377 (0.27%)"
    ]
}